In fact, the three mAbs approved for colon cancer immunotherapy, bevacizumab and cetuximab or panitumumab, are not completely specific for target colon cancer, as they recognize the vascular endothelial growth factor (VEGF) or the epidermal growth factor receptor (EGFR), respectively (Sliwkowski and Mellman 2013). The gene discussed is VEGFA; the disease is malignant colon neoplasm.